Publications by authors named "F Citarella"
Importance: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy.
Objective: To develop a supervised deep learning-based ICI response prediction method; evaluate its performance alongside other known predictive biomarkers; and assess its association with clinical outcomes in patients with advanced NSCLC.
Article Synopsis
- The MET exon 14 skipping mutation is a rare occurrence in non-small-cell lung cancer (NSCLC), found in 3%-4% of cases, and this study analyzes the characteristics and treatment outcomes for patients from the Italian ATLAS registry.
- In a cohort of 146 advanced METex14 NSCLC patients, treated primarily with MET inhibitors capmatinib (38%) and tepotinib (23%), the response rate was 37% and the disease control rate was 62%, with median progression-free survival of 6.6 months and overall survival of 10.7 months.
- Adverse effects were noted in 12% of patients, with serious complications requiring dose modifications in a small percentage, indicating
Guidelines historically recommended mono-chemotherapy for the 1 line treatment of elderly patients with non-small cell lung cancer (NSCLC) and poor performance status (PS). Nowadays, there is no clear indication whether chemo-immunotherapy (chemo-IO) combinations can be effectively delivered in this population. We collected induction chemotherapy data in consecutive patients with advanced NSCLC treated with carboplatin-based chemotherapy regimens plus pembrolizumab, to compute the received dose intensity (RDI) from standard regimens or patient-tailored regimens modified due to age, comorbidities and PS.
View Article and Find Full Text PDFCompared to other malignancies, few studies have investigated the role of family history of cancer (FHC) in patients with lung cancer, yielding largely heterogeneous results. We performed a systematic literature review in accordance with PRISMA guidelines, searching the PubMed and Scopus databases from their inception to November 25, 2023, to identify studies reporting on the role of FHC in patients with lung cancer. A total of 53 articles were included, most with a retrospective design and encompassing a variety of geographical areas and ethnicities.
View Article and Find Full Text PDFPurpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers.
Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs).